Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis

• DOI: 10.1007/s00508-019-01595-8
• Publication Date: 2020-01-07T09:04:00Z
• Authors: Robert Wakolbinger; Christian Muschitz; Jacqueline Wallwitz; Gerd Bodlaj; Xaver Feichtinger; Jakob E. Schanda; Heinrich Resch; Andreas Baierl; Peter Pietschmann
• Keywords: Sclerostin; Microarchitecture

Summary Background Patients with hepatic cirrhosis are at increased risk of bone loss. Recent work on areal mineral density has reported contradictory findings. As the assessment microarchitecture is complex, a search was made for correlations new serum markers turnover. Current data sclerostin levels in patients fracture divergent and to date only one study examined cirrhosis. Therefore, aim this evaluate test microarchitecture. Methods This performed 32 recently diagnosed controls. The parameters were assessed by high-resolution peripheral quantitative computed tomography. Sclerostin detected via ELISA that detects active receptor interaction site loop 2 core region. Results slightly, but not significantly lower patient group, compared In contrast, alcoholic liver had than A significant correlation (BMD) trabecular observed group. However, there hardly any between Conclusion cirrhosis, related altered BMD. disease, low concentrations seen.